Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Meaghan Marnell
- Phone Number: (336) 888-0435
- Email: clinicaltrials@vtvtherapeutics.com
Study Locations
-
-
California
-
Modesto, California, United States, 95355
- Recruiting
- Paradigm Clinical Research -Modesto
-
Principal Investigator:
- Gopika Gangupantula, MD
-
San Diego, California, United States, 92108
- Recruiting
- Paradigm Clinical Research Centers, LLC
-
Principal Investigator:
- Schafer Boeder, MD
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Barbara Davis Center for Diabetes
-
Principal Investigator:
- Halis Kaan Akturk, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Recruiting
- Atlanta Diabetes Associates
-
Principal Investigator:
- Bruce W Bode, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- UNC Eastowne Medical Office Building
-
Principal Investigator:
- Klara Klein, MD, PhD
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- Texas Diabetes & Endocrinology, P.A.
-
Principal Investigator:
- Thomas Blevins, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Participants >= 18 years of age
- Fasting C-peptide levels <0.6 ng/ml
- Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
- Have been diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cadisegliatin 800 mg QD, then Placebo
If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Other Names:
Placebo (insulin alone) |
|
Experimental: Placebo, then Cadisegliatin 800 mg QD
If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Other Names:
Placebo (insulin alone) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the change in Time in Range (TIR)
Time Frame: last 2 weeks of the two 6-week treatment periods
|
Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last 2 weeks of the two 6-week treatment periods
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Time In Tight Range (TITR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Time Above Range (TAR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Time Below Range (TBR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Glucose Management Indicator (GMI) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Glucose variability (GV) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period
|
Time in Range (TIR) > 70% |
last 2 weeks of each treatment period
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Time Frame: 12 weeks
|
Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Time Frame: 12 weeks
|
Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
Time Frame: 12 weeks
|
Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
12 weeks
|
|
Assess incidence of Serious Adverse Events (SAEs)
Time Frame: 14 weeks
|
Number of Serious Adverse Events (SAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
Time Frame: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug |
14 weeks
|
|
Assess incidence of Adverse Events of Special Interest (AESIs)
Time Frame: 14 weeks
|
Number of adverse events of special interest (AESIs) |
14 weeks
|
|
Change from baseline in average daily total insulin dose
Time Frame: last week of the two 6-week treatment periods
|
Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last week of the two 6-week treatment periods
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Maria Alba, MD, vTv Therapeutics LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TTP399-206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.